CDK12 and prostate cancer: While CDK12 loss occurs in a minority (3–7%) of metastatic prostate cancer cases, it correlates with accelerated metastatic spread and heightened genome instability, characterized by increased focal tandem duplications in cancer-related genes.409 CDK12 has also been identified as a critical oncogenic protein for prostate cancer cell survival.